Impact: Further studies are needed to better understand the recent breast cancer trends.
Introduction
Breast cancer incidence rates among US white women remarkably decreased by about 7% between 2002 and 2003, with the decrease more pronounced for women ages 50-69 than for other age groups and for ER+ tumors than for ER-tumors (1) (2) . This decrease was temporally related to the dramatic drop in the use of postmenopausal hormone therapy (HT) following the publication of the Women's Health Initiative (WHI) study findings in July 2002 on the adverse health effects of combined HT use, including increased risk of breast cancer (3) (4) . Several recent publications reported female breast cancer incidence rates continued to decrease among white women (5) (6) (7) (8) . However, none of these studies exclusively examined the trend after 2003.
In this paper, we examined breast cancer incidence rates among non-Hispanic (NH) Central Cancer Registries (NAACCR) Hispanic Identification Algorithm (NHIA). Incidence rates were also stratified by age at diagnosis (ages ≥ 30, 30-39, 40-49, 50-59, 60-69, 70+) and estrogen receptor status (ER+ and ER-). All rates were adjusted for reporting delays using SEER 13-9 adjustment ratios. Delay adjustment ratios are not available for Hispanics, thus adjustment ratios for whites were used. The percentage of cases with missing ER status ranged from 18% in 2000 to 7% in 2007, therefore we imputed ER status for those with missing information using chained equation methods (10) . The following covariates were used to impute ER status: age, (Table S1 ). However, the incidence rate in NH white women ages 60-69 increased from 402. (Table S1 ). 
and blacks). Similar to white women, there were no significant changes in overall breast cancer incidence rates among NH black and Hispanic women in any age group during [2003] [2004] [2005] [2006] [2007] (Table   S1) Tables 1 and 2 present the prevalence of HT use by race/ethnicity and age among women without and with hysterectomy, respectively. Combined estrogen and progestin (E+P) use was highest among NH white women, followed by Hispanic, and NH black women (Table 1) .
E+P use continued to decline over this time interval, although the decreases from 2005 to 2008
were generally smaller in both absolute and relative terms, compared to the decreases from 2000 to 2005. By 2008, only 2.8% of NH white women ages 50 and older, 1.5% of Hispanic and 0.9% of NH black women used E+P therapy. Use of estrogen alone (E only) was more common than E+P and use was highest among NH white women, followed by NH Black and Hispanic women ( Table 2 ). Similar declines in E only use were observed among each age and racial/ethnic group. (Table 1) . Second, the stable trends in incidence rates may reflect improved sensitivity of mammography without influence of HT, as HT increases breast density (16) and compromises the diagnostic performance of mammograms and breast biopsies (17) . It may also in part reflect the relatively stable rates of screening mammography in the US since 2000 (18) . Similar to white women, ER+ breast cancer rates significantly increased among NH black women ages 40-49. Non-significant increases in ER+ rates were also observed among NH black women ages 50-69. Consistent with previous studies (20, 23) , we also found a non-significant increase in ER-breast cancer in black women, although in our study the increase was limited to women ages 60-69. It is not clear why ER+ and ER-breast cancer rates among black women may have increased for certain age groups. One hypothesis is that recent breast cancer incidence trends in black women reflect trends in the prevalence of obesity, which increased through the mid-2000s (20) . Also, reasons for the higher rates of ER-breast cancer in black women compared to white and Hispanic women are not fully understood, but are thought to reflect a complex interaction of genetic, environmental, and behavioral factors (24) .
This study has several strengths and limitations. This is a descriptive study of US populationbased breast cancer incidence rates from the 12 SEER registries with high quality data, representing 14% of the US population. Another important strength of this study was our (data not shown) and our estimates for 2000 were similar. Another limitation of this study was our statistical power to detect subtle trends in breast cancer incidence in age-specific analyses of NH black and Hispanic women due to smaller case counts, as well as for the less prevalent ER-breast cancers.
Conclusion
In summary, the sharp decline in breast cancer incidence rates that occurred from 
